[Dose-response relationship of intravenous administration of benzquinamide hydrochloride for suppression of cytostatic-induced emesis].
Benzquinamide-HCl (Promecon), a new antiemetic agent, was applied as an intravenous infusion in different doses for prevention of cancer chemotherapy-induced vomiting to 108 patients. All the patients chosen for this trial were treated with regimens containing cisplatin and/or doxorubicin. An antiemetic effect in 70% or more of the cases was noted in doses of 300-500 mg benzquinamide-HCl per day. In conclusion, doses less than this range will not be successful for prevention of vomiting caused by cytotoxic drugs with a high emetic action.